Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB732462
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
SB732462 is an investigational therapeutic HIV vaccine developed by GSK. It was evaluated in Phase 1 clinical trials to assess safety, reactogenicity, and immunogenicity in HIV-infected individuals, including those on highly active antiretroviral therapy (HAART) and treatment-naïve subjects. The vaccine is an adjuvanted formulation administered via intramuscular injection. It was part of GSK's efforts to develop an immunotherapy that could potentially control viral replication or enhance the immune response against HIV-1. While specific antigen details are not widely publicized in early trial documentation, it was part of a broader program investigating recombinant protein-based vaccines combined with proprietary adjuvant systems.
- Other names
- HIV Vaccine 732462
Beyond the preview
Go deeper on SB732462.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB732462.